Donaldson, a Minneapolis, MN-based provider of filtration products and solutions, acquired Univercells Technologies, a Nivelles, Belgium-based provider of a producer of innovative biomanufacturing solutions.
Univercells Technologies is being acquired from Gamma Biosciences and Univercells SA and will be a part of the Donaldson Life Sciences segment. The deal’s consideration was €136 million on a cash-free, debt-free basis and subject to closing adjustments
With the acquisition, Donaldson will expand its operations.
Led by Mathias Garny, chief executive officer, Univercells Technologies is a provider of biomanufacturing technologies to achieve advanced therapies and vaccines production from R&D to commercial scales. The company’s product offering includes the scale-X™ single-use structured fixed-bed bioreactor for the intensified production of viruses used in cell and gene therapy, viral vaccines and other therapeutics. In addition, its automated NevoLine™ Upstream platform incorporates filtration to provide integrated up- and mid-stream processing capabilities in a single unit driving productivity improvements, reduced operational footprints and greater consistency of results.
Univercells Technologies has over 100 employees globally. The company generated approximately €10 million of revenue in calendar 2022.
Founded in 1915 and led by Tod Carpenter, chairman, president and chief executive officer, Donaldson (NYSE: DCI) is a leader in technology-led filtration products and solutions, serving a broad range of industries and advanced markets. Its diverse employees at over 140 locations on six continents partner with customers to solve complex filtration challenges.
